{"filing":{"accession_number":"0001171843-26-005454","cik":"0001505065","ticker":"BRSYF","company_name":"Brainsway Ltd.","form":"6-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"f6k_081226.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1505065/000117184326005454/f6k_081226.htm"},"events":[{"id":27140,"run_id":24715,"accession_number":"0001171843-26-005454","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This is an investor presentation deck disclosing BrainsWay's Q2 2026 financial performance, strategic platform evolution, and growth initiatives. The exhibit reports record system shipments (+42% YoY), revenue growth (+35%), gross margin expansion (75%), and profitability metrics (Adj. EBITDA +141%, Operating Income +281%, Net Income +60%), alongside strategic announcements of clinic network expansion, home therapy investment (Neurolief $11M convertible), and international scaling. While the presentation contains financial results, it is structured as a strategic business update and investor communication rather than a formal earnings release or periodic financial report. The disclosure is material as it communicates significant operational momentum, margin expansion, and strategic capital deployment that would affect a reasonable investor's assessment of the company's growth trajectory and execution.","company_name":"Brainsway Ltd.","ticker":"BRSYF","filing_date":"2026-08-12","form":"6-K","submitted_at":null,"items":[{"id":28538,"accession_number":"0001171843-26-005454","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This is an investor presentation deck disclosing BrainsWay's Q2 2026 financial performance, strategic platform evolution, and growth initiatives. The exhibit reports record system shipments (+42% YoY), revenue growth (+35%), gross margin expansion (75%), and profitability metrics (Adj. EBITDA +141%, Operating Income +281%, Net Income +60%), alongside strategic announcements of clinic network expansion, home therapy investment (Neurolief $11M convertible), and international scaling. While the presentation contains financial results, it is structured as a strategic business update and investor communication rather than a formal earnings release or periodic financial report. The disclosure is material as it communicates significant operational momentum, margin expansion, and strategic capital deployment that would affect a reasonable investor's assessment of the company's growth trajectory and execution.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:03:00.258561+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28538,"accession_number":"0001171843-26-005454","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This is an investor presentation deck disclosing BrainsWay's Q2 2026 financial performance, strategic platform evolution, and growth initiatives. The exhibit reports record system shipments (+42% YoY), revenue growth (+35%), gross margin expansion (75%), and profitability metrics (Adj. EBITDA +141%, Operating Income +281%, Net Income +60%), alongside strategic announcements of clinic network expansion, home therapy investment (Neurolief $11M convertible), and international scaling. While the presentation contains financial results, it is structured as a strategic business update and investor communication rather than a formal earnings release or periodic financial report. The disclosure is material as it communicates significant operational momentum, margin expansion, and strategic capital deployment that would affect a reasonable investor's assessment of the company's growth trajectory and execution.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:03:00.258561+00:00","company_name":"Brainsway Ltd.","ticker":"BRSYF","filing_date":"2026-08-12"}]}